SynthesisFrontiers in psychiatry2026
Peripheral blood immune markers associated with negative symptoms in first episode psychosis: a systematic review.
Synthesis in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Negative symptoms are a core feature of psychotic disorders, evident from the first episode of psychosis (FEP), and are strongly associated with poor functional outcomes. Increasing evidence suggests that immune dysregulation may contribute to negative symptom expression in FEP individuals; however, findings remain heterogeneous. This systematic review aimed to synthesise recent evidence on the association between peripheral blood immune markers and negative symptoms in FEP. Methods: A systematic search of PubMed and Scopus was conducted following PRISMA guidelines. Observational studies published within the last five years were included if they assessed peripheral blood immune markers and negative symptoms in individuals with FEP and included a healthy control group. Study quality was evaluated using the Newcastle-Ottawa Scale. Findings were synthesised narratively due to methodological heterogeneity. Results: Seven case-control studies met the inclusion criteria, comprising predominantly young adults with FEP, including both antipsychotic-naïve and minimally treated individuals. Across studies, a broad range of immune markers was assessed, most commonly IL-6, IL-1β, and TNF-α. FEP individuals generally showed elevated levels of inflammatory markers compared with controls. Associations between immune markers and negative symptoms were modest but consistently positive, with IL-1β and TNF-α showing the most reproducible associations with negative symptom severity. Findings for other cytokines were more variable. Notably, most studies relied on total negative symptom scores, and none examined symptom subdomains or dimensional constructs. Conclusions: Peripheral immune dysregulation, particularly involving IL-1β and TNF-α, appears to be associated with negative symptom severity in FEP. However, heterogeneity in immune measurement and symptom assessment limits mechanistic interpretation. Future studies should prioritise dimensional assessment of negative symptoms, stratification by inflammatory profiles, and integration of cellular immune phenotyping to better elucidate immune-symptom relationships in early psychosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.